SEC Form 4 · accession 0001387131-17-001436
Adamis Pharmaceuticals Corp · ADMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ronald B. Moss
Officer — Chief Medical Officer
Period of report
Feb 28, 2017
Accepted (ET)
Mar 16, 2017 · 6:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000887247
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $3.45 | Feb 28, 2017 | A | 210,000 | A | — | Feb 28, 2027 | Common Stock | 210,000 | 210,000 | D |
Explanation of responses
- F1The option vests and becomes exercisable as to 1/3 of the shares subject to the option on the first anniversary of the grant date, and thereafter with respect to 1/36 of the shares subject to the option on each monthly anniversary of the grant date, and otherwise vests and becomes exercisable as provided in the option agreement relating to the option.